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Background
Locally Advanced Breast Cancer patients require neoadju-
vant chemotherapy (NACT), surgery and radiation ther-
apy to optimize the chance of a cure. Pathological
responses to NACT, are strongly associated with long-term
outcome. Cisplatin has shown antitumor activity in breast
cancer, shows synergy with paclitaxel and antitumor activ-
ity in anthracycline-resistant breast tumors. As NACT,
Paclitaxel-Cisplatin (PC) achieves high pathological
responses. On the other hand, dose dense chemotherapy
has improved free and overall survival in early breast can-
cer. This phase II trial was set to evaluate the pathological
complete response (pathCR) of this regimen based on 4
cycles of adriamycin/cyclophosphamide (AC) followed
by weekly (dose dense) PC. Secondary endpoints were to
evaluate the safety profile and recurrence-free survival.
Materials and methods
Patients with histological confirmation of breast cancer in
stage IIB-IIIC and aged 18–75 years. Patients also had
good performance status [ECOG] score ≤2, adequate
hematological, cardiovascular, renal, and hepatic func-
tions. Patients were excluded if they were pregnant or
breast feeding or if they had other malignant tumors.
Patients received 4 cycles of AC at 60/600 mg/m2 every 21
days followed by weekly PC at 80/30 mg/m2 respectively,
at the end of chemotherapy patients underwent surgery.
Results
A total of 33 patients were included and were evaluable
for toxicity and response; the analysis was done in the
intention-to-treat. One patient showed paclitaxel hyper-
sensitivity and was removed from the study. Three
patients remained inoperable after chemotherapy, hence,
received preoperative radiation. Median age was 48 years-
old (26–73), 66.7% of cases were in stage IIIA and IIIB,
tumor median size was 6 cm (2.5–16), node median size
was 3 cm (2–16), all patients had clinical positive nodes.
ER or PgR were positive in 60.6%, HER2 was positive in
36.4% (determined by IHC or FISH). The pathCR rate was
30%, the complete nodal response was 52%. At 18
months of follow-up 2 patients had distant relapse for a
91% of recurrence free-survival. The regimen was well tol-
erated with grade III-IV toxicity observed in 6% of cases.
Conclusion
The addition of cisplatin to paclitaxel is well tolerated
with no significant increase in toxicity. Interestingly, the
30% of pathCR observed seems superior to other regi-
mens without cisplatin.
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